Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Hanwha’s biosimilar of Enbrel approved for marketing
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Nov 14, 2014 16:29:58
The Ministry of Food and Drug Safety approved Hanwha Chemicals’ Davictrel 25mg, the biosimilar of Enbrel, on November 11.

Hanwha sent its marketing application for Davictrel in 2012, but the approval was deferred as the MOFDS asked more documents. Hanwha cancelled the application at that time and reapplied in June 2014.

Enbrel sales were 29.3 billion won last year in South Korea, but the global sales reached 9 trillion won. Hanwha is likely to try to enter the global market with its biosimilar of Enbrel.
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com